Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 5/20 | 0.72 |
| ▸ | PDPK1 | O15530 | 9/20 | 0.70 |
| ▸ | SGK1 | O00141 | 6/20 | 0.59 |
| ▸ | AURKA | O14965 | 3/20 | 0.53 |
| ▸ | TGFBR1 | P36897 | 3/20 | 0.53 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.53 |
| ▸ | CDK2 | P24941 | 2/20 | 0.53 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.53 |
| ▸ | CHUK | O15111 | 1/20 | 0.53 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.53 |
| ▸ | KDR | P35968 | 1/20 | 0.53 |
| ▸ | SYK | P43405 | 1/20 | 0.53 |
| ▸ | JAK3 | P52333 | 1/20 | 0.53 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.53 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.52 |
| ▸ | CDK4 | P11802 | 1/20 | 0.52 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.52 |
| ▸ | CCND1 | P24385 | 1/20 | 0.52 |
| ▸ | CCND3 | P30281 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6489879 | 0.88 | JAK2 (0.65) | JAK2PDPK1SGK1AURKATGFBR1 | |
| SCHEMBL421269 | 0.85 | JAK2 (0.77) | JAK2PDPK1SGK1AURKATGFBR1 | |
| SCHEMBL4502873 | 0.85 | PDPK1 (0.60) | JAK2PDPK1SGK1AURKATGFBR1 | |
| SCHEMBL4494112 | 0.85 | JAK2 (0.77) | JAK2PDPK1SGK1AURKATGFBR1 | |
| SCHEMBL3361070 | 0.84 | JAK2 (1.00) | JAK2PDPK1SGK1AURKATGFBR1 | |
| SCHEMBL12907241 | 0.84 | JAK2 (1.00) | JAK2PDPK1SGK1AURKATGFBR1 | |
| SCHEMBL6485242 | 0.82 | PDPK1 (1.00) | JAK2PDPK1AURKATGFBR1AURKB | |
| SCHEMBL4494073 | 0.82 | JAK2 (0.72) | JAK2PDPK1SGK1AURKATGFBR1 | |
| SCHEMBL6479941 | 0.82 | JAK2 (0.72) | JAK2PDPK1SGK1AURKATGFBR1 | |
| SCHEMBL3359710 | 0.82 | FGFR1 (0.72) | JAK2PDPK1AURKATGFBR1AURKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101962365-A | Aminoindazole derivatives as protein-kinase inhibitors | AVENTIS PHARMA SA | 2011-02-02 | — | — | CN | claimed |
| US-6949579-B2 | Aminoindazole derivatives and intermediates, preparation thereof, and pharmaceutical compositions thereof | AVENTIS PHARMA S.A. (FR) | 2005-09-27 | — | — | US | claimed |
| CN-1656078-A | Aminoindazole derivatives as protein kinase inhibitors | AVENTIS PHARMA SA (FR) | 2005-08-17 | — | — | CN | claimed |
| US-20040014802-A1 | Aminoindazole derivatives and intermediates, preparation thereof, and pharmaceutical compositions thereof | AVENTIS PHARMA S.A. (FR) | 2004-01-22 | — | — | US | claimed |
| EP-1487804-B1 | AMINOINDAZOLE DERIVATIVES AS PROTEIN-KINASE INHIBITORS | AVENTIS PHARMA SA (FR) | 2014-02-26 | — | — | EP | disclosed |
| CN-101962365-A | Aminoindazole derivatives as protein-kinase inhibitors | AVENTIS PHARMA SA | 2011-02-02 | — | — | CN | disclosed |
| US-6949579-B2 | Aminoindazole derivatives and intermediates, preparation thereof, and pharmaceutical compositions thereof | AVENTIS PHARMA S.A. (FR) | 2005-09-27 | — | — | US | disclosed |
| CN-1656078-A | Aminoindazole derivatives as protein kinase inhibitors | AVENTIS PHARMA SA (FR) | 2005-08-17 | — | — | CN | disclosed |
| US-20040014802-A1 | Aminoindazole derivatives and intermediates, preparation thereof, and pharmaceutical compositions thereof | AVENTIS PHARMA S.A. (FR) | 2004-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040014802-A1 | Aminoindazole derivatives and intermediates, preparation thereof, and pharmaceutical compositions thereof | CYP2C8, NR0B2, NR2C2 | JAK2 1774/4885PDPK1 4495/4885SGK1 3581/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.